CLASS ACTION UPDATE for CCXI, PRVB and HMPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / June 24, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
CCXI Shareholders Click Here: https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=17164&wire=1
PRVB Shareholders Click Here: https://www.zlk.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17164&wire=1
HMPT Shareholders Click Here: https://www.zlk.com/pslra-1/home-point-capital-inc-loss-submission-form?prid=17164&wire=1
* ADDITIONAL INFORMATION BELOW *
ChemoCentryx, Inc. (NASDAQ:CCXI)
CCXI Lawsuit on behalf of: investors who purchased November 26, 2019 - May 6, 2021
Lead Plaintiff Deadline: July 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=17164&wire=1
According to the filed complaint, during the class period, ChemoCentryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Provention Bio, Inc. (NASDAQ:PRVB)
PRVB Lawsuit on behalf of: investors who purchased November 2, 2020 - April 8, 2021
Lead Plaintiff Deadline: July 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17164&wire=1
According to the filed complaint, during the class period, Provention Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Home Point Capital Inc. (NASDAQ:HMPT)
This lawsuit is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired Home Point common stock pursuant and/or traceable to the Company's January 29, 2021 initial public offering.
Lead Plaintiff Deadline : August 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/home-point-capital-inc-loss-submission-form?prid=17164&wire=1
According to the filed complaint, (i) Home Point's aggressive expansion of its broker partners would dramatically increase the Company's expenses; (ii) the mortgage industry was anticipating industry-wide decreased gain-on-sale margins as a result of rising interest rates in 2021 and Home Point would be subject to the same competitive pressures; (iii) accordingly, the Company had overstated its business and financial prospects; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/653020/CLASS-ACTION-UPDATE-for-CCXI-PRVB-and-HMPT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
